- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07655505
Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair
15. juni 2026 opdateret af: Intuitive Surgical
A Prospective, Multicenter Clinical Investigation of the Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair (MVr)
This study aims to test the safety and effectiveness of Force Feedback instruments used during robotic-assisted mitral valve repair with the da Vinci Surgical System, Model IS5000 (dV5).
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
30
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Manish Bharara
- E-mail: manish.bharara@intusurg.com
Undersøgelse Kontakt Backup
- Navn: Jennifer McCrea
- Telefonnummer: 303-956-0363
- E-mail: jennifer.mccrea@intusurg.com
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Age ≥22 years.
- Subjects with mitral regurgitation (MR) resulting from primary (degenerative) etiology with normal ventricular function (left ventricular function > 40%) provided that annuloplasty or ventricular repair is feasible robotically.
- Subjects with moderate-severe (Grade 3) or severe (Grade 4) mitral regurgitation (MR) confirmed by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE) within 60 days of surgery or evaluation for surgery.
- Subjects with low-moderate operative risk (Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score of <4%).
- Subjects that are able to provide written informed consent using the study informed consent form prior to the study.
- Subjects that are willing to comply with protocol-specified follow-up visits.
- Subjects must be candidates for minimally invasive surgery (no contraindications to robotic approach). Based on the study Investigator's clinical judgement, the Subject is deemed suitable to undergo multiport robotic-assisted surgery for mitral valve repair.
Exclusion Criteria:
PREOPERATIVE EXCLUSION CRITERIA:
- Subjects with symptomatic mitral regurgitation determined to be at prohibitive risk for mitral valve surgery.
- Subjects with previous mitral valve surgery, transcatheter repair, or annuloplasty.
- Subjects with prior cardiac surgery (endoscopic, open, or robotic) or ipsilateral thoracic surgery (open, endoscopic, or robotic).
- Subjects with planned emergent procedure (e.g., cardiogenic shock, acute decompensation requiring immediate surgery).
- Subjects requiring surgery with multiple stages (i.e., mitral repair cannot be completed in a single procedure).
- Subject with planned major concomitant surgery for a different medical condition (e.g., coronary artery bypass, cancer resection unrelated to mitral regurgitation).
- Subjects with non-reparable anatomy.
- Subjects with severe pulmonary hypertension (systolic Pulmonary Artery Pressure >70 mmHg).
- Subjects with severe renal insufficiency (estimated Glomerular Filtration Rate <30 mL/min/1.73m²) or liver failure (Child-Pugh C).
- Subjects with active infection.
- Subjects with contraindication to anesthesia/surgery (e.g., severe frailty, uncorrectable coagulopathy).
- Subjects with any past or ongoing condition, or personal circumstance, that in the Investigator's judgment places the Subject at high surgical risk, deems them unsuitable for mitral valve repair, or might interfere with study participation or data collection (e.g., severe chronic obstructive pulmonary disease, uncontrolled diabetes, immunocompromised state, non-compliance).
- Subjects with severe aortic/tricuspid valve disease requiring concurrent open surgery.
- Subjects who are pregnant, suspected pregnancy, or breastfeeding.
- Subjects currently participating in another investigational drug/device study or participation in a significant-risk investigational device study within the past 6 months.
- Subject with inability to complete follow-up (e.g., geographic inaccessibility, dementia).
- Subjects who belong to a vulnerable population (e.g., prisoners, cognitively impaired individuals unable to consent).
INTRAOPERATIVE EXCLUSION CRITERIA:
- Subject with hemodynamic or respiratory instability that precludes the Investigator from performing the Robotic Assisted Surgery (RAS).
- Subject in whom inadequate visualization makes a minimally invasive approach not feasible, as determined by the Investigator assessment prior to docking the robot.
- Subject with adhesions, scarring, and disease status in the body which, in the opinion of the investigator, limits the ability to perform the minimally invasive procedure.
- Subject has any other condition that, in the judgment of the Investigator, might interfere with the collection of complete quality data.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Mitral valve repair including the use of force feedback instruments
Patients with moderate-severe or severe mitral regurgitation resulting from primary (degenerative) etiology who are candidates for robotic-assisted mitral valve repair.
|
Robotic-assisted mitral valve repair including the use of Force Feedback instruments
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of major adverse events
Tidsramme: 30 days postoperative
|
The primary safety endpoint will be evaluated by the incidence of major (Clavien-Dindo Grade III or higher) adverse events related to the use of Force Feedback instruments during robotic-assisted mitral valve repair.
|
30 days postoperative
|
|
Residual Mitral Regurgitation Grade on a Transthoracic Echocardiogram (TTE)
Tidsramme: Postoperative Day 2-7
|
The primary effectiveness endpoint will be evaluated as residual mitral regurgitation of moderate (Grade 2) or less measured by an echocardiogram after robotic-assisted mitral valve repair.
|
Postoperative Day 2-7
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. juni 2026
Primær færdiggørelse (Anslået)
31. december 2026
Studieafslutning (Anslået)
1. juni 2027
Datoer for studieregistrering
Først indsendt
10. juni 2026
Først indsendt, der opfyldte QC-kriterier
15. juni 2026
Først opslået (Faktiske)
18. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
18. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
15. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ISI dV5 MVr-01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ja
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Mitral Regurgitation (MR)
-
Sun Yat-sen UniversityRekrutteringMitral insufficiens | Mitral Regurgitation (MR)Kina
-
Segeberger Kliniken GmbHRekrutteringMitral Regurgitation (MR)Tyskland
-
Mitrassist Lifesciences Limited Co., Ltd.RekrutteringMitral Regurgitation (MR)Kina
-
Beijing HospitalIkke rekrutterer endnu
-
Artivion Inc.Ikke rekrutterer endnuMitral Regurgitation (MR)Forenede Stater, Det Forenede Kongerige, Italien
-
China National Center for Cardiovascular DiseasesAfsluttetPædiatrisk hjertekirurgi | Mitral Regurgitation (MR)Kina
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, France; GIRCI IDFIkke rekrutterer endnu
-
Columbia UniversityAmerican Heart AssociationRekrutteringAortastenose | Aorta regurgitation | Valvulær hjertesygdom | Klappesygdom, aorta | Tricuspid regurgitation (TR) | Mitral Regurgitation (MR)Forenede Stater
-
Abbott Medical DevicesAfsluttetFunktionel mitral regurgitation | Degenerative Mitral RegurgitationDen Russiske Føderation
-
Mitre Medical Corp.BSWRI Cardiac Imaging Core Lab (CICL)Ikke rekrutterer endnuIskæmisk mitral regurgitation | Funktionel mitral regurgitationForenede Stater